INDICATIONS AND USAGE

Pemetrexed for Injection is a folate analog metabolic inhibitor indicated:

• in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

• in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. 

• as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. 

• as a single agent for the treatment of patients with recurrent, metastatic nonsquamous, NSCLC after prior chemotherapy. 

Limitations of Use: 

Pemetrexed for Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. 

• initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.